Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer

NCT07567846 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT07567846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07567846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 29, 2026
Completion date
December 30, 2027
Enrollment
260 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer, metastatic prostate cancer